BioPharma Credit Says Lexicon-Sanofi Settlement Enhances Loan Assets

(Alliance News) - BioPharma Credit PLC said Wednesday the termination of an alliance between ...

Alliance News 11 September, 2019 | 6:19PM
Email Form

(Alliance News) - BioPharma Credit PLC said Wednesday the termination of an alliance between Sanofi SA and Lexicon Pharmaceuticals Inc enhances the collateral value behind its loan to Lexicon.

BioPharma - a pharmaceutical debt investor - funded USD124.5 million of a USD150 million loan to Lexicon, which matures in 2022. This loan is secured on "substantially all" of the assets of Lexicon, including its rights to the Zynquista diabetes drug.

On Monday, Sanofi and Lexicon terminated an alliance for the development and commercialisation of Zynquista - the brand name of sotagliflozin - as well as a settlement of disputes.

Under the deal, Lexicon regained all rights to Zynquista and assumed all responsbility for development and commercialisation of the type one and type two diabetes treatment. Sanofi also paid Lexicon USD260 million.

On Wednesday, BioPharma said it believed that the "settlement announced by Lexicon further enhances the value of the collateral supporting the loan" issued by BioPharma to Lexicon.

Shares in BioPharma closed 0.5% higher at USD1.02 in London on Wednesday.

By Ahren Lester;

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
BioPharma Credit Ord 0.89 USD 1.14 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites